A Reversal for ANGLE plc Is Not Near. The Stock Declines Again

 A Reversal for ANGLE plc Is Not Near. The Stock Declines Again

The stock of ANGLE plc (LON:AGL) is a huge mover today! The stock decreased 7.14% or GBX 4.5 on November 3, hitting GBX 58.5. About 122,139 shares traded hands. ANGLE plc (LON:AGL) has declined 15.83% since April 6, 2016 and is downtrending. It has underperformed by 17.04% the S&P500.
The move comes after 9 months negative chart setup for the GBX 43.77M company. It was reported on Nov, 3 by Barchart.com. We have GBX 52.65 PT which if reached, will make LON:AGL worth GBX 4.38M less.

More notable recent ANGLE plc (LON:AGL) news were published by: Marketwired.com which released: “ANGLE plc: Annual Report and Accounts and Notice of AGM” on September 09, 2016, also Marketwired.com with their article: “Angle PLC Announces New Publications Utilising Parsortix” published on April 29, 2016, Marketwired.com published: “ANGLE plc: Notice of GM” on November 01, 2016. More interesting news about ANGLE plc (LON:AGL) were released by: Marketwired.com and their article: “ANGLE PLC: Research Published in Clinical Chemistry” published on September 30, 2016 as well as Businesswire.com‘s news article titled: “Medical University of Vienna Research Demonstrates Value of ANGLE plc’s ‘Blood …” with publication date: April 21, 2015.

ANGLE plc is a holding company. The Company’s principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The company has a market cap of 43.77 million GBP. The Firm is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. It currently has negative earnings. The Company’s Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells from blood.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment